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As a target, the JNK pathway has been implicated in roles including cell death, prolifera-
tion, and inflammation in variety of contexts which span cardiovascular disease, neurode-
generative pathologies, and cancer. JNK1 and JNK2 have recently been demonstrated to
function independently, highlighting a new parameter in the study of the JNK pathway.
In order for JNK1 and JNK2-specific roles to be defined, better tools need to be
employed. Previous studies have relied upon the broad spectrum JNK inhibitor,
SP600125, to characterize the role of JNK signaling in a number of cell lines, including
the breast cancer cell line MCF-7. In line with previous literature, our study has demon-
strated that SP600125 treatment inhibited c-Jun and JNK phosphorylation and MCF-7
proliferation. However, in addition to targeting JNK1, JNK2, and JNK3, SP600125 has
been previously demonstrated to suppress the activity of a number of other serine/thre-
onine kinases, making SP600125 an inadequate tool for JNK isoform-specific roles to be
determined. In this study, lentiviral shRNA was employed to selectively knockdown
JNK1, JNK2, and JNK1/2 in MCF-7 cells. Using this approach, JNK phosphorylation was
fully inhibited following stable knockdown of respective JNK isoforms. Interestingly,
despite suppression of JNK phosphorylation, MCF-7 cell proliferation, cell cycle progres-
sion, or cell death remained unaffected. These findings raise the question of whether
JNK phosphorylation really is pivotal in MCF-7 cell growth and death or if suppression
of these events is a result of one of the many off-targets cited for SP600125.
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1 | INTRODUCTION
Protein kinases are attractive candidates as targets for the develop-
ment of new drugs due to the integral role they play in regulating
key inflammatory signaling pathways that underpin a host of disease
states.1 Members of the serine/threonine protein kinase family, such
as c-Jun N-terminal kinase (JNK), have been under investigation in
the cancer field due to the their essential roles in cell survival,
growth, and death processes.2,3 The major challenge these targets
present in drug development is the high degree of structuralAbbreviations: ANOVA, analysis of variance; BSA, Bovine Serum Albium; HCC,
hepatocellular carcinoma; JNK, Jun N-terminal kinase; MEFs, mouse embryonic fibroblasts;
NT, nontarget; WT, wild type.
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similarity across family members that make specificity difficult to
achieve without off targets and side effects.4,5
The JNK family consists of three proteins, JNK1, JNK2, and
JNK3, with JNK1 and JNK2 expressed ubiquitously while JNK3
expression is restricted to the brain, heart, and testis.6 JNK1 and
JNK2 has recently been demonstrated to function independently
therefore before success can be made in developing more selective
drugs that target this pathway, there has to be a clearer understand-
ing of the JNK1- and JNK2-specific roles. While inhibitors exist that
suppress the JNK pathway, so far they display poor potency7 and
are nonselective.8 Many studies investigating JNK as a target have
used pharmacological inhibition of the signaling pathway by
SP600125. In addition to targeting JNK1, JNK2, and JNK3,
SP600125 has been previously demonstrated to suppress the activ-
ity of a number of other serine/threonine kinases,9 which makes
SP600125 an inadequate tool for JNK1- and JNK2-specific roles to
be determined. Success in this area has been best illustrated in stud-
ies using JNK1 and JNK2 knock out mouse models. Studies using
mouse embryonic fibroblasts (MEFs) derived from JNK knockout
mice have revealed differences in JNK isoform function. Sabapathy
et al have demonstrated that JNK1 activated the transcription factor
c-Jun and played a role in promoting proliferation of MEFs, whereas
JNK2 functioned as a negative regulator by promoting c-Jun degra-
dation and slowing down fibroblast proliferation.10 JNK1 and JNK2
have also been shown to function differently in cell death induced
by ultraviolet (UV) radiation.11 JNK1 knockout resulted in partial pro-
tection against UV radiation in MEFs, whereas JNK2/ MEFs
behaved similarly to wild type (WT). These findings demonstrate that
JNK isoforms can function differently and independently in both cell
death and cell growth processes in MEFs, however, a detailed under-
standing of JNK1 and JNK2 function needs to be more widely
explored in human cell models. This has been best exemplified in the
cancer field where different roles for JNK isoforms have been
demonstrated using a variety of different tools.
In hepatocellular carcinoma (HCC), JNK has been linked to both
the pathogenesis and poor prognosis of the disease.12 In this study,
lentiviral approaches were used to stably knockdown JNK1, JNK2, and
JNK1/2 in the HuH-7 HCC cell line to investigate the effects of JNK
knockdown on cell proliferation. JNK1 and JNK1/2 knockdown pro-
duced a decrease in proliferation, whereas JNK2 knockdown had no
significant effect on proliferation which translated to the development
of smaller tumors when implanted into nude mice, clearly linking JNK1
but not JNK2 to the tumorigenesis of HCC cells. Other studies have
used the JNK inhibitor, SP600125, to pharmacologically inhibit JNK
activity to implicate this pathway in breast cancer cell models.13,14
Studies carried out in the MCF-7 breast cancer cell line have shown
that the JNK pathway is required for cell death in response to UV15
and taxol16 and also for MCF-7 proliferation and cell cycle progres-
sion.15 Given the selectivity issues of SP600125, the roles attributed
to JNK1 and JNK2 remain unclear, therefore JNK as a target in this
context needs to be investigated further using more selective tools.
Here we explore JNK1 and JNK2 function in breast cancer cell lines
using lentiviral shRNA to selectively knock down these targets. In order
for comparisons to be drawn, SP600125 will be used to ensure that
previously published data can be reproduced in the MCF-7 cell line.
2 | MATERIALS AND METHODS
2.1 | Lentivirus production and lentiviral infection
shRNA targeting JNK1 (TAGATGCATCTATTACCAG), JNK2 (TCATG
ATCTAGCTCCATCT) and nontargeting control (ATCTCGCTTGGGCG
AGAGTAAG) cloned into a pGIPZ lentiviral plasmid were purchased
from DharmaconTM. These transfer vectors (2 lg) were cotransfected
into HEK-293T cells together with 2 lg of packaging vector pCMV—
dR8.2 dvpr (Addgene), 2 lg of envelope vector pCMV-VSV-G
(Addgene), and 12 lL of Turbofect (Thermoscientific) transfection
reagent in media lacking antibiotics. After 12-16 hours, media were
replenished with complete media. After a further 24 hours, the media,
now containing lentivirus particles, were harvested and the media
were replenished with a final harvest carried out after a further
24 hours. Lentivirus was concentrated 1009 using Lenti-X-concentra-
tor (Takara Bio USA Inc.). Lentiviruses were referred to as NT for non-
targeting and JNK1 and JNK2 for the targeted silencing of JNK1 and
JNK2. For lentiviral infection, MCF-7 cells were grown to 50% conflu-
ency and infected with either NT, JNK1, JNK2, or co transfected with
JNK1 and JNK2 lentivirus for 48 hours. For selection, media were
replaced with complete media containing 1 lg/mL of puromycin for a
further 48 hours or until all uninfected cells died. Cells were selected
every passage to maintain stable lines.
2.2 | Cell culture
The breast cancer MCF-7 cell lines were maintained in Dulbecco’s
modified Eagle’s medium containing 10% (v:v) fetal calf serum,
27 mg/mL glutamine, and penicillin/streptomycin (250 units/mL and
25 mg/mL, respectively) at 37°C in a humidified air containing 5%
CO2. For experiments, cells were seeded at specific densities: Wes-
tern blot and FACS analysis (150 000 cells/mL), MTT (10 000 cells/
mL), and clonogenics (120 cells/mL).
2.3 | Stimulations for western blot analysis
Cells were starved for 24 hours and stimulated with 10% FCS for
1 hour or 30 J/m2 UV radiation for 24 hours before cells were har-
vested in 19 Laemmli Sample Buffer. For taxol experiments, cells
were stimulated with 1% DMSO or 20 nmolL1 of taxol for
24 hours before cells were harvested in 19 Laemmli Sample Buffer.
For SP600125 (Sigma-Aldrich) experiments, cells were pretreated
with 30 lmolL1 of SP600125 for 1 hour prior to stimulation with
10% FCS or 30 J/m2 UV radiation.
2.4 | Western blot
For protein detection, cellular protein was subjected to 10% SDS-
PAGE and blotted onto nitrocellulose membrane. The membranes
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were blocked for nonspecific binding for 2 hours using 50 mmolL1
Tris buffer (pH 7.4), 150 mmolL1 NaCl, 0.1% (v:v) Tween-20 (TBS-
T), containing 5% Bovine Serum Albium (BSA) (w:v). Blots were then
incubated overnight in 0.5% BSA (w:v) TBS-T with primary antibody.
Blots were washed for 15 minutes in TBS-T before being incubated
for 2 hours in 0.5% BSA (w:v) TBS-T with 1:7500 dilution of HRP-
conjugated secondary antibody. Blots were developed using ECL
reagent followed by exposure to Kodak X-ray film. Antibodies: pJNK
1:1500 (cell signaling technology #9251), pc-Jun 1:1000 (Santa Cruz
SC-822), cleaved PARP 1:1000 (cell signaling technology #5625),
JNK1 1:7500 (cell signaling technology #3708), JNK2 1:7500 (cell




On Day 1, cells from control, NT, JNK1, JNK2, and JNK1/2 cell lines
were seeded onto 96-well plates and incubated for 8 days at 37°C
in a humidified air containing 5% CO2, media were replenished on
day 4. On days 2, 4, 6, and 8, 10 lL of MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) (Sigma–Aldrich) was added to
each well and cells were incubated for 2 hours. Media were then
removed from the wells and 100 lL of DMSO was added to dissolve
the purple formazan product. Absorbance (570 nm) was then mea-
sured to estimate cell viability.
For experiments with SP600125, MCF-7 cells were treated with
a lower concentration of SP600125 (20 lmolL1) due to repeated
treatment after the initial measurement on day 2 and on days 4
and 6. Controls of media alone and 1% DMSO were also replen-
ished.
2.5.2 | Cell viability
Cells were seeded onto 96 well plates and stimulated for 24 hours
with either 1% DMSO or 20 nmolL1 taxol. 10 lL of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma-
Aldrich) was added to each well and cells were incubated for
2 hours. Media were then removed from the wells and 100 lL of
DMSO was added to dissolve the purple formazan product. Absor-
bance (570 nm) was then measured to estimate cell viability.
2.6 | Clonogenic assay
Cells were seeded onto 60 mm2 dishes and incubated overnight at
37°C in a humidified air containing 5% CO2. Cells were starved for
24 hours and then exposed to 10 J/m2 of UV radiation. Media were
replaced with complete media and plates were incubated for
12-15 days, with media replenished on days 5 and 10. After incuba-
tion, the media were removed; cells were washed with PBS, fixed
with methanol, and stained with Giemsa for 20 minutes. After stain
was removed, formed colonies were counted manually and survival
fractions were calculated. For SP600125 experiments, cells were
pretreated with 30 lmolL1 of SP600125 1 hour before exposure
to UV radiation, the media remained on the cells 6 hours after expo-
sure and were then replaced with complete media and followed the
same course as previously described.
2.7 | FACS
2.7.1 | Cell cycle
For cell cycle progression analysis, MCF-7 cells were starved for
24 hours and then replenished with complete media for 24 and
48 hours with samples collected at each stage. Cells were trypsi-
nized and fixed in 70% ethanol in PBS at 4°C for 20 minutes—
2 days. Cells were then washed in PBS, centrifuged at 1800g for
10 minutes and then resuspended in 250 lL of PBS. 50 lg/mL of
RNAse A (Sigma-Aldrich) was added to each sample and incubated
for 30 minutes at 37°C. 50 lg/mL of Propidium Iodide (Sigma-
Aldrich) was added to each sample and tubes were vortexed before
analysis. Samples were read in FACSCanto flow cytometer and data
were analyzed using FACS Diva software (FACS scan, Becton Dick-
inson, Oxford, UK). A total of 10000 events were measured per
sample and gating was determined using PI-stained populations.
Cell cycle events were gated on G1, S, G2/M, and sub G1and the
% of total events in each phase was measured. For SP600125
experiments, cells were treated with 30 lmolL1 of SP600125 or
1% DMSO when media were replenished after 24 hours of starva-
tion. For taxol experiments, cells were collected the same as above
after 24 or 48 hours treatment with 20 nmolL1 of taxol or 1%
DMSO.
2.7.2 | Apoptosis
After treatment with 1% DMSO or 20 nmolL1 taxol for 48 hours
or 500 lmolL1 H2O2 for 24 hours as positive control, cells were
trypsinized and washed twice in PBS. As suggested by company
guidelines, cells were resuspended in 100 lL of 19 Annexin V
binding buffer (BD bioscience) and stained with 5 lL of APC-
Annexin V (BD bioscience) for 15 minutes at room temperature.
Samples were read in FACSCanto flow cytometer and data were
analyzed using FACS Diva software (FACS scan, Becton Dickinson,
Oxford, UK). A total of 10 000 events were measured per sample
and gating was determined using APC-Annexin V individually
stained cells and data were represented as the % of Annexin V-
positive cells.
2.8 | Data analysis and processing
All statistics were calculated using GraphPad Prism version 5.01.
Datasets were analyzed for statistical significance using either a one
or two-way analysis of variance (ANOVA). P values <.05 were con-
sidered significant and means +/ standard errors of the mean
(SEM) are depicted in all figures.
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3 | RESULTS
3.1 | Inhibition of JNK by SP600125 causes cell
cycle arrest and a reduction in cell proliferation
Previous studies investigating JNK function in MCF-7 cells have
used transient methods of inhibition15 or knockdown17 to analyze
their effects on cellular processes. The JNK inhibitor SP600125 is
commonly used, therefore we initially sought to confirm if
SP600125 could inhibit JNK signaling in MCF-7 cells in our studies
and investigate the effect of inhibition on cell growth. Treatment
with 10% FCS increased the expression of pc-Jun by 1.59-
fold  0.16, pJNK (54 kDa) by 2.39-fold  0.75 and pJNK (46 kDa)
by 4.72-fold  0.65 when compared with nontreated cells (Fig-
ure 1A). Similar results were produced by cells that were pretreated
with 1% DMSO (1.17  0.21, 2.49  0.76, and 4.36  0.76,
respectively), however, pretreatment with SP600125 reduced the
levels of phosphorylated c-Jun and JNK back to basal levels after
stimulation with 10% FCS (Figure 1A). Proliferation was also
reduced over 8 days when compared with the DMSO-treated cells
(Figure 1B). Control and DMSO-treated cells grew steadily over the
8 days with an average fold growth of 3.4  1.2 and 2.7  0.9,
respectively (Figure 1B). While treatment with SP600125 inhibited
cell growth to 1.5-fold  0.2, suggesting that JNK is involved in
MCF-7 cell growth. To understand how JNK inhibition may be pre-




pc-Jun pJNK 46 kDa pJNK 54 kDa
F IGURE 1 Inhibition of JNK by SP600125 causes cell cycle arrest and a reduction in cell proliferation. Cells were treated with media alone,
1% DMSO or SP600125 as stated in methods and the effects of JNK inhibition on (A) pc-Jun expression, (B) proliferation, and (C) cell cycle
progression were analyzed. Data represent the mean  SEM of 3 independent experiments where *P < .05, **P < .01 and ***P < .001
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progression was investigated using FACS analysis (Figure 1C). Treat-
ment with SP600125 produced an arrest which was represented by
an increase of 21.7%  2.3 in the population of cells in the G2/M
phase of the cell cycle when compared with DMSO-treated cells.
These results coincide with those published by,15 thus confirming
reproducibility of this JNK phenomenon in MCF-7 cells.
3.2 | Generation of MCF-7 cell lines containing JNK
individual isoform knockdown
After confirming that inhibition of JNK by SP600125 influenced cell
cycle progression and proliferation, we next investigated which JNK
isoforms played a role in these processes. The Lentiviral delivery
method of shRNA has been used to knockdown JNK isoforms in dif-
ferent cell lines including human epithelial,18 human liver cancer,19
and mouse mammary tumor cells.20 As this has allowed differences
in isoform function to be determined in these studies, we used len-
tiviral shRNA to generate MCF-7 cell lines containing stable knock-
down of JNK1, JNK2, and JNK1/2. Western blotting experiments
confirmed that protein levels were reduced by 93.21%  2.03 and
88.76%  6.49 for JNK1 and JNK2, respectively, in lines containing
single knockdown and 70.54%  6.39 (JNK1) and 92.47  3.65
(JNK2) in double knockdown lines when compared with control cells
(Figure 2).
3.3 | Knockdown of JNK isoforms has no effect on
MCF-7 proliferation, cell cycle progression or
phosphorylation of c-Jun
After cell lines were successfully generated and knockdown was
confirmed, these cells were used to investigate the effects of JNK
isoform knockdown on cell cycle progression using FACS analysis.
Our data show that over 48 hours there was a decrease in the per-
centage of cells in the G1 phase of the cell cycle (control
29.12%  3.0, NT 23.43  4.3, JNK1 19.7  3.1, JNK2
24.37  4.2, and JNK1/2 22.83  5.2) and an increase in the S
(control 14.90%  0.6, NT 14.04  1.6, JNK1 14.77  2.0, JNK2
14.20  2.1, and JNK1/2 13.0  2.5) and G2/M phase (control
14.67%  1.9, NT 8.76  2.8, JNK1 5.06  1.1, JNK2 9.84  2.7,
and JNK1/2 10.03  2.6) (Figure 3A). Interestingly there were not
any major differences observed between the cell lines, including the
control and nontarget (NT) lines (Figure 3A). There was also no cell
cycle arrest produced by the knockdown of JNK demonstrating con-
trasting results when compared with the experiments using
SP600125. Similarly, JNK isoform knockdown had little effect on the
phosphorylation of cJun (Figure 3B) and the proliferation of MCF-7
cells (Figure 3C) where all cells produced a fold growth of between
five and sevenfold with slight variation between experiments taken
into consideration. Interestingly, when experiments using SP600125
were repeated in JNK isoform knockdown cells, loss of JNK expres-
sion did not alter the effects produced by SP600125 (Figure S1).
3.4 | UV-induced cell death is independent of JNK
in MCF-7 cells
Since the knockdown of JNK isoforms did not affect processes
involved in cell growth, we wanted to investigate whether the same
occurred when analyzing cell death. JNK has been previously
demonstrated to play a key role in UV-induced cell death in MEFs
where knockout of JNK prevented cell death for up to 28 hours
after exposure to UV radiation.11 Following serum starvation, MCF-7
cells were treated with 30 J/m2 of UV radiation for 24 hours and
the expression of cleaved PARP was measured (Figure 4A). Similar
to the cell growth experiments, knockdown of JNK isoforms did not
produce a great change in cleaved PARP expression with all cell lines
producing a fold stimulation of between five and eightfold (Control
7.54  0.79, NT 5.95  1.42, JNK1 knockdown 5.22  1.31, JNK2
knockdown 4.93  0.65, and JNK1/2 knockdown 7.1  1.53. This
was confirmed by clonogenic assay where cells were exposed to a
lower dose of 10 J/m2, immediately replenished with complete
media and then incubated for a longer period of 12-15 days. Again,
all cell lines produced a similar survival fraction (0.5-0.6) after treat-
ment with UV (Figure 4B), suggesting that JNK does not play a role
in UV-induced cell death in MCF-7 cells.
F IGURE 2 Confirmation of JNK1,
JNK2, and JNK1/2 knockdown in MCF-7
cell lines. MCF-7 cells were collected at
each passage and expression levels were
analyzed using Western blot. Results show
representative blot of (A) JNK1 and (B)
JNK2 knockdown. Data represent the
mean  SEM of 4 independent
experiments where ***P < .001
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F IGURE 3 Cell cycle progression, proliferation, and activation of c-Jun is independent of JNK. (A) Cells were starved for 24 hours and then
replenished with complete media for 48 hours, samples were analyzed by FACS for the % of cells in G1, S, and G2/M of the cell cycle. (B) The
number of viable cells measured by MTT represented as a fold increase relative to the number of viable cells on day 2. (C) Cells were starved
for 24 hours, stimulated with 10% FCS for 1 hour and then collected and expression levels of pc-Jun, JNK1, JNK2, and GAPDH were analyzed
by Western Blot. Data represent the mean  SEM of 3 independent experiments
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3.5 | Taxol-induced cell cycle arrest and death is
independent of JNK
To understand if JNK played a role in cell death produced by other
stimulants, we treated MCF-7 cells with 20 nmolL1 of taxol for
24-48 hours and assessed the effects of JNK isoform knockdown on
cell death. As expected, taxol-induced an increase in the expression
of cleaved PARP by 26.2 fold  10.56 (control), 32.78 fold  12.05
(NT), 25.15 fold  1.38 (JNK1), 19.98 fold  9.43 (JNK2), and 28.62
fold  6.61 (JNK1/2) (Figure 5A) after 24 hours, although the fold
stimulation varied between the different cell lines, these differences
were insignificant when compared with control and NT samples.
Taxol also produced a decrease of 37.59%  3.59 (control),
34.57%  12.10 (NT), 35.65% + 1.10 (JNK1), 38.74%  5.06
(JNK2), and 35.09%  5.27 (JNK1/2) in the number of viable cells
after 24 hours (Figure 5B) and an increase of 14.56%  5.54 (con-
trol), 14.94%  4.84 (NT), 12.27%  7.39 (JNK1), 9.7%  3.69
(JNK2), and 11.17%  5.60 (JNK1/2) in the percentage of apoptotic
cells after 48 hours of treatment with taxol (Figure 5C). Similar to
the UV experiments, knockdown of JNK did not reverse cell death
induced by Taxol over 24 or 48 hours. Finally, the role of JNK iso-
forms in taxol-induced cell cycle arrest was investigated. As
expected, treatment with taxol for 24 hours caused the percentage
of cells in the G2/M phase of the cell cycle to increase by
31.73%  4.8, 34.1%  4.26, 37.87%  2.77, 35.40%  1.42, and
36.07%  3.20 for control, NT, JNK1, JNK2, and JNK1/2 knock-
down lines, respectively. Again, this was the similar across all 5 cell
lines confirming that JNK does not play a role in taxol-induced cell
death in MCF-7 cells.
4 | DISCUSSION
Extensive research has been carried out to demonstrate that the
JNK pathway, and now more specifically the individual JNK isoforms
themselves, play key roles in both cancer cell survival and cell death
processes.21 The outcome of this signaling is determined by a num-
ber of variables including cell type,22 cell location,23 stimulant type,24
length of stimulation,25 and protein location.26 Due to the plethora
of variables involved, characterization of the JNK pathway can be
difficult as every model, cell type or technique can produce a differ-
ent result. Many studies investigating JNK function to date have
used pharmacological inhibition of the signaling pathway by
SP600125. Although this inhibitor does block JNK signaling, it has
also been reported to inhibit 13 other protein kinases, including
AMPK, CDK2, and SGK.9 Although JNK is an attractive target, there
is yet to be a successful drug developed which can inhibit this pro-
tein without off-target effects.8 In order for progress to be made in
this area, more selective approaches need to be adopted to ensure
that the effects observed are due to JNK and not one of the many
off-targets inhibited by SP600125.
In our own investigation, we managed to recapitulate previously
published findings using the SP600125 inhibitor. If the pharmacolog-
ical data generated using SP600125 were to be solely relied upon,
our data would similarly support a role for JNK signaling in MCF-7
cells proliferation and cell cycle progression. However the data pre-
sented in our study highlight the critical need of adopting a more
selective approach when interrogating the JNK pathway and not
relying solely on the use of SP600125.
In this study, stable and selective lentiviral knockdown of JNK1
and JNK2 was achieved in MCF-7 cells. Although consistent JNK
isoform knockdown was achieved, no effect on cell death induced
by UV radiation or taxol was observed. This was confirmed using a
variety of approaches including cell viability assays, Western blotting,
and FACS analysis. These results were surprising given that previous
studies using SP600125 had proposed that JNK play a role in both
UV15,27 and taxol-28 induced cell death in MCF-7 cells. Similarly,
knockdown of JNK1 or JNK2 in our studies had no effect on cell
growth. This was observed for both proliferation and cell cycle pro-
gression experiments. Again, these results were surprising given that
(A)
(B)
F IGURE 4 UV-induced cell death is
independent of JNK. (A) Cells were starved
for 24 hours, exposed to 30 J/m2 of UV
radiation for 24 hours and then samples
were collected and expression levels of
cleaved PARP, pJNK, JNK1, JNK2, and
GAPDH were analyzed. (B) Cells were
starved for 24 hours, exposed to 10 J/m2
UV radiation, cells were replenished with
complete media and incubated for 12-
15 days. A clonogenic assay was used to
measure successful colonies formed for
both exposed and unexposed cells. Data
represent mean  SEM of 3 independent
experiments
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JNK signaling has been linked to both proliferation17 and cell cycle
progression15 in MCF-7 cells when treated with SP600125. JNK is a
known regulator of c-Jun in a number of different cell lines.10,29
While loss of JNK in our studies resulted in inhibition of JNK phos-
phorylation, this did not impact phosphorylation of c-Jun. Interest-
ingly, inhibition of JNK with SP600125 clearly inhibited MCF-7
proliferation and phosphorylation of c-Jun, producing contrasting
results to experiments conducted using lentiviral knockdown of JNK.
The fact that both methods of protein targeting resulted in inhi-
bition of JNK phosphorylation suggests that the cellular events
downstream of UV and taxol are independent of JNK. In light of the
numerous off-targets cited for SP600125, we cannot rule out the
possibility that inhibition of these kinases may be a contributing fac-
tor to the contrasting results produced in this study (summarized in
Figure 6). When combination experiments were carried out using
SP600125 in JNK isoform-specific knockdown cell lines, SP600125
clearly inhibited MCF-7 proliferation and cell cycle progression. This
suggests that the actions of SP600125 may be independent of JNK.
Two such proteins inhibited by SP600125, namely SDK30 and





F IGURE 5 Taxol-induced cell death is independent of JNK. Cells were treated with DMSO or taxol for (A, B, D) 24 hours or (C) 48 hours
and samples were collected and analyzed for (A) expression levels of cleaved PARP, pJNK, JNK1, JNK2, and JNK1/2 by Western Blot. (B) Cell
viability using an MTT assay, (C) Apoptosis using FACS analysis of Annexin V positive cells and (D) cell cycle arrest induced by taxol using
FACS analysis gated on PI positive cells represented as the number of positive cells in G1, S, G2/M, and Sub G1 phase of the cell cycle. Data
represent the mean  SEM of 3 independent experiments
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cycle progression. Inhibition of these kinases may be contributing to
the pronounced effects observed in SP600125 studies.
Trying to determine JNK isoform function in cancer is very chal-
lenging due to the differences in JNK function between cancer
types,19,32 however, with more selective tools becoming available it
should be possible. Studies using JNK knockout animals clearly pre-
sent a good rationale for why targeting JNK isoforms may be of
therapeutic value,10 however firm translation of these findings into
human cell models is crucial. For example, JNK1 but not JNK2 was
shown to be required for UV-mediated death in MEFs.33 However,
in this study JNK knockdown had no effect on MCF-7 cell death
induced by UV exposure. Differences in the translation of these
events from mouse cells to human cell models may account for
these conflicting findings. The use of JNK knockdown, or gene dele-
tion approaches such as CRISPR, in other cell systems may help to
shed some light on the role for JNK in human cell growth and
death.
What is clear from our study is that any interpretations derived
from studies that rely solely on the use of SP600125 need to be
treated with caution when attributing the JNK pathway to MCF-7
cell growth and death. Due to the sheer number of other serine/
threonine kinases inhibited by SP600125, it would be wise to
employ more selective ways to validate the role of JNK in cancer
cell function. While shRNA approaches have their own set of chal-
lenges to ensure complete knock down of protein levels are
achieved, the availability of gene editing approaches such as CRISPR
will pave the way for a better fundamental understanding of the role
of JNK (or any other target) in human cancer cell function. This will
be essential if progress in the field is to be made and new targets
are to be identified for anticancer therapies.
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